New Leaders, Quarterly Dividends, Positive Clinical Results, and Data Presentations - Research Report on Quintiles, CR Bard,

    New Leaders, Quarterly Dividends, Positive Clinical Results, and Data
      Presentations - Research Report on Quintiles, CR Bard, Theravance,
                  Immunomedics and Progenics Pharmaceuticals

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

New York, December 17, 2013

New York, December 17, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Quintiles
Transnational Holdings Inc. (NYSE: Q), CR Bard Inc. (NYSE: BCR), Theravance
Inc. (NASDAQ: THRX), Immunomedics Inc. (NASDAQ: IMMU) and Progenics
Pharmaceuticals Inc. (NASDAQ: PGNX). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Quintiles Transnational Holdings Inc. Research Report

On December 12, 2013, Quintiles Transnational Holdings Inc. (Quintiles)
announced that it has appointed W. Scott Evangelista as its President for
Integrated Commercial Services and Solutions. The Company said that in this
new role, Evangelista is responsible for leading Quintiles' global Commercial
organization and the ongoing development and delivery of its related service
offerings. Prior to Quintiles, Evangelista was a principal at Deloitte
Consulting LLP's LifeSciences practice, where he served as commercial practice
leader. Commenting on the appointment, Tom Pike, CEO of Quintiles said,
"Scott's experience working on and developing innovative commercial solutions
for the biopharmaceutical industry is a tremendous addition to our already
world-class team. During his career, Scott has been involved in many aspects
of the commercial organization, all while delivering a consistent track record
of growth and innovation. He brings a range of expertise and experience that I
believe will help take our commercial customer support to the next level." The
Full Research Report on Quintiles Transnational Holdings Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/9f5c_Q

CR Bard Inc. Research Report

On December 11, 2013, CR Bard Inc.'s (CR Bard) Board of Directors declared a
regular quarterly dividend of $0.21 per share on Bard's common stock.
According to the Company, the current dividend indicated an annual dividend
rate of $0.84 per share. The aforesaid dividend is payable on January 31, 2014
to shareholders of record at the close of business on January 21, 2014. The
Full Research Report on CR Bard Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/141e_BCR

Theravance Inc. Research Report

On December 6, 2013, Theravance Inc. (Theravance) announced positive results
from a phase III efficacy and safety study of fluticasone furoate
"FF"/vilanterol "VI" designed to support a potential filing for an asthma
indication for adults in the US. The Company said that these results will
inform GSK's discussions with the FDA on the regulatory requirements of an
asthma indication for FF/VI in the US. Theravance CEO Rick E. Winningham said,
"There is an ongoing unmet medical need among patients with asthma. This is an
important outcome for FF/VI and we will continue working with GSK to determine
how we can make this potential treatment available to appropriate patients who
could benefit from a new asthma medicine." The Full Research Report on
Theravance Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/fa70_THRX

Immunomedics Inc. Research Report

On December 9, 2013, Immunomedics Inc. (Immunomedics) announced promising
activity with veltuzumab in relapsed immune thrombocytopenia. Immunomedics
said that veltuzumab, administered subcutaneously as a single agent, produced
an overall objective response rate of 49% in 47 evaluable patients with
relapsed immune thrombocytopenia (ITP), including 15 patients (32%) who
reported a complete response. For the 23 patients who responded, median time
to relapse from initial veltuzumab dose was 9.2 months, with 11 patients (48%)
maintaining their response for more than 1 year. Further, the Company said
that Veltuzumab showed activity across all dose levels tested, including the
lowest dose of 80 mg x 2, and was active in patients with limited disease
duration of 1 year or less, as well as in more heavily pretreated patients
with chronic refractory disease. Cynthia L. Sullivan, President and CEO of the
Company commented, "We are very pleased with these promising results. The fact
that some patients relapsed to TPOR agonists responded to veltuzumab is
particularly encouraging. We are currently evaluating various options for
further clinical development of veltuzumab in this and other autoimmune
disease indications, as well as in oncology, including licensing arrangements
and collaborations with outside study groups." The Full Research Report on
Immunomedics Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/c20d_IMMU

Progenics Pharmaceuticals Inc. Research Report

On December 6, 2013, Progenics Pharmaceuticals Inc. (Progenics
Pharmaceuticals) presented findings from a Phase I study of its Imaging Agent,
1404, at the meeting of the Society for Urologic Oncology in Rockville,
Maryland. The poster, entitled A Phase I Study of TC-99-M-MIP-1404 SPECT/CT to
Identify and Localize High Grade Cancer in the Prostate Gland, was presented
by Kevin Slawin, M.D., Director, Vanguard Urologic Institute, Memorial
Hermann-TMC. Dr. Slawin said, "In this study, the presence of primary prostate
cancer was correctly identified in eight of eight patients by SPECT/CT imaging
with 1404. An imaging agent with this high degree of accuracy has the
potential to allow doctors and their patients to focus on the treatment of
aggressive cancers while more conservatively managing low grade cancers." The
Full Research Report on Progenics Pharmaceuticals Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/ce17_PGNX

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.